glp 1 medicaid Coverage of and Spending on GLP-1s Medicaid Coverage of and Spending
Description
This paper reviews the physiological, pharmacologic, and clinical foundations linking GLP-1 RA therapy to reproductive outcomes
Eli Lilly CEO David Ricks announces details of the Medicare GLP-1 bridge program, offering weight loss medications like Fondeo and Zepbound for $50 per month to 20 million eligible Medicare Part D patients starting July 1.
In late April 2025, the FDA issued a key update regarding the use of compounded GLP-1 receptor agonists like semaglutide and tirzepatide
PMID: 37288303
